FDA Greenlights Groundbreaking Pancreatic Cancer Drug
By Editor • August 27, 2026 • 1 min read
In a significant breakthrough, the FDA has approved a new treatment for advanced pancreatic cancer developed by Revolution Medicines. This innovative therapy targets a genetic cause of the disease, marking a first in the fight against this aggressive cancer.
Clinical trials reveal promising results, with patients receiving the drug as a second-line treatment achieving a median overall survival of 13.2 months, a stark contrast to the 6.7 months seen with standard chemotherapy.
In other news, the Trump administration is set to announce new drug-pricing agreements with various midsized biotech firms, aimed at aligning U.S. Medicaid drug costs with those in foreign markets.
Source: www.statnews.com
#drug pricing #FDA #pancreatic cancer #Revolution Medicines #Trump administration
